Osteosarcoma

Polydatin has meaningful preclinical activity in osteosarcoma, including radiosensitisation and reversal of doxorubicin resistance.

Overview

The osteosarcoma literature highlights cell-cycle effects, apoptosis induction, and treatment-resistance modulation.

Key findings

• Promotes S-phase cell-cycle arrest in osteosarcoma cells

• Shows radiosensitising effects when combined with radiation

• Overcomes doxorubicin resistance through TUG1/Akt-related signalling changes

• Increases Bax/Bcl2 ratio and suppresses β-catenin-related survival pathways

• Reduces viability, migration, and proliferation in U2OS and MG63 models

Practical interpretation

Osteosarcoma is a good example of polydatin acting as both a growth inhibitor and a resistance-modulating adjunct.

References

Uncovering the Anticancer Potential of Polydatin: A Mechanistic Insight
https://pmc.ncbi.nlm.nih.gov/articles/PMC9656535/